BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

900 related articles for article (PubMed ID: 19814687)

  • 21. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
    Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Jin UR; Park JS
    J Korean Med Sci; 2014 Nov; 29(11):1493-500. PubMed ID: 25408580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
    Purroy N; Bergua J; Gallur L; Prieto J; Lopez LA; Sancho JM; García-Marco JA; Castellví J; Montes-Moreno S; Batlle A; de Villambrosia SG; Carnicero F; Ferrando-Lamana L; Piris MA; Lopez A
    Br J Haematol; 2015 Apr; 169(2):188-98. PubMed ID: 25521006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is inactivation of O6-methylguanine DNA methyltransferase still a favorable prognostic factor of patients with diffuse large B-cell lymphoma in the era of R-CHOP chemotherapy?
    Lee GW; Kang JH; Kim IS; Kim HG; Ko GH; Lee JH; Kim DC; Song DH; Yang JW; Lee JS
    Leuk Lymphoma; 2009 Dec; 50(12):1992-8. PubMed ID: 19860620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
    Thieblemont C; Tilly H; Gomes da Silva M; Casasnovas RO; Fruchart C; Morschhauser F; Haioun C; Lazarovici J; Grosicka A; Perrot A; Trotman J; Sebban C; Caballero D; Greil R; van Eygen K; Cohen AM; Gonzalez H; Bouabdallah R; Oberic L; Corront B; Choufi B; Lopez-Guillermo A; Catalano J; Van Hoof A; Briere J; Cabeçadas J; Salles G; Gaulard P; Bosly A; Coiffier B
    J Clin Oncol; 2017 Aug; 35(22):2473-2481. PubMed ID: 28426350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Go SI; Park MJ; Song HN; Kim HG; Kang MH; Lee HR; Kim Y; Kim RB; Lee SI; Lee GW
    J Cachexia Sarcopenia Muscle; 2016 Dec; 7(5):567-576. PubMed ID: 27104110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
    Ferrara F; Ravasio R
    Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy.
    Halaas JL; Moskowitz CH; Horwitz S; Portlock C; Noy A; Straus D; O'Connor OA; Yahalom J; Zelenetz AD
    Leuk Lymphoma; 2005 Apr; 46(4):541-7. PubMed ID: 16019482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease.
    O'Reilly SE; Hoskins P; Klimo P; Connors JM
    Ann Oncol; 1991 Jan; 2 Suppl 1():17-23. PubMed ID: 1710485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study.
    Chang JE; Seo S; Kim KM; Werndli JE; Bottner WA; Rodrigues GA; Sanchez FA; Saphner TJ; Longo WL; Kahl BS
    Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):379-84. PubMed ID: 21030351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
    Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
    Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.
    Chiappella A; Tucci A; Castellino A; Pavone V; Baldi I; Carella AM; Orsucci L; Zanni M; Salvi F; Liberati AM; Gaidano G; Bottelli C; Rossini B; Perticone S; De Masi P; Ladetto M; Ciccone G; Palumbo A; Rossi G; Vitolo U;
    Haematologica; 2013 Nov; 98(11):1732-8. PubMed ID: 23812930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up].
    Cheng ZX; Zou SH; Li F; Li JM; Wang JM; Chen FY; Cao JN; Wang C; Wei Z; Cheng YF
    Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):257-60. PubMed ID: 22781712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: results of a randomized, phase III, non-inferiority trial.
    Shi Q; He Y; Yi HM; Mu RJ; Jiang XF; Fu D; Dong L; Qin W; Xu PP; Cheng S; Song Q; Chen SJ; Wang L; Zhao WL
    Cancer Commun (Lond); 2023 Aug; 43(8):896-908. PubMed ID: 37403255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Upfront autologous stem cell transplantation for untreated high-risk diffuse large B-cell lymphoma in patients up to 60 years of age.
    Takasaki H; Hashimoto C; Fujita A; Matsumoto K; Taguchi J; Kuwabara H; Yamazaki E; Koharazawa H; Fujita H; Fujisawa S; Ishii Y; Yamamoto W; Motomura S; Tomita N; Ishigatsubo Y; Sakai R
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):404-9. PubMed ID: 23763919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
    Peyrade F; Jardin F; Thieblemont C; Thyss A; Emile JF; Castaigne S; Coiffier B; Haioun C; Bologna S; Fitoussi O; Lepeu G; Fruchart C; Bordessoule D; Blanc M; Delarue R; Janvier M; Salles B; André M; Fournier M; Gaulard P; Tilly H;
    Lancet Oncol; 2011 May; 12(5):460-8. PubMed ID: 21482186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
    Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
    Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study.
    García-Suárez J; Bañas H; Arribas I; De Miguel D; Pascual T; Burgaleta C
    Br J Haematol; 2007 Jan; 136(2):276-85. PubMed ID: 17233819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
    Musolino A; Boggiani D; Panebianco M; Vasini G; Salvagni S; Franciosi V; Ardizzoni A
    Cancer; 2011 Mar; 117(5):964-73. PubMed ID: 20960528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma.
    Kayamori K; Shono K; Onoda M; Yokota A
    Hematology; 2019 Dec; 24(1):52-59. PubMed ID: 30101679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation.
    Strüßmann T; Fritsch K; Baumgarten A; Fietz T; Engelhardt M; Mertelsmann R; Ihorst G; Duyster J; Finke J; Marks R
    Br J Haematol; 2017 Sep; 178(6):927-935. PubMed ID: 28643323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.